Evidence map›Paper›PMID 23420391›Full record

ArticlePolymer bulletin (Berlin, Germany)2013

Formulation of salicylate-based poly(anhydride-ester) microspheres for short- and long-term salicylic acid delivery.

Roselin Rosario-Meléndez, Michelle A Ouimet, Kathryn E Uhrich

Abstract read
In one paragraph

Article in Polymer bulletin (Berlin, Germany), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Polyanhydride Chemistry.Biomacromolecules · 2022
    Review
  3. Article
  4. Poly(anhydride-ester) gemcitabine: Synthesis and particle engineering of a high payload hydrolysable polymeric drug for cancer therapy.Journal of controlled release : official journal of the Controlled Release Society · 2021
    Article
  5. Article
  6. Article
  7. PolyMorphine: an innovative biodegradable polymer drug for extended pain relief.Journal of controlled release : official journal of the Controlled Release Society · 2012
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Roselin Rosario-MeléndezRutgers, The State University of New Jersey, Department of Chemistry and Chemical Biology, 610 Taylor Road, Piscataway, New Jersey 08854, United States.
Michelle A Ouimet
Kathryn E Uhrich

Funding

Local Modulation of Inflammation to Heal Cranial-facial Bone DefectsR01DE019926 · NIDCR · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI O'CONNOR, J PATRICK, RICCI, JOHN · 2009 to 2012
$2.5M
BIODEGRADABLE POLYMERIC PRODRUGSR01DE013207 · NIDCR · RUTGERS THE ST UNIV OF NJ NEW BRUNSWICK · PI UHRICH, KATHRYN ELIZABETH · 2000 to 2009
$2.2M
NIDCR NIH HHS R01 DE013207NIDCR NIH HHS R01 DE019926
6 · The paper itself

Abstract

The formulation of salicylate-based poly(anhydride-ester) (PAE) microspheres was optimized by altering polymer concentration and homogenization speed to improve the overall morphology. The microspheres were prepared using three salicylate-based PAEs with different chemical compositions comprised of either a heteroatomic, linear aliphatic, or branched aliphatic moiety. These PAEs broadened the range of complete salicylic acid release to now include days, weeks and months. The molecular weight (M(w)), polydispersity index (PDI) and glass transition temperature (T(g)) of the formulated polymers were compared to the unformulated polymers. In general, the M(w) and PDI exhibited decreased and increased values, respectively, after formulation, whereas the T(g) changes did not follow a specific trend. Microsphere size and morphology were determined using scanning electron microscopy. These microspheres exhibited smooth surfaces, no aggregation, and size distributions ranging from 2-34 m in diameter. In vitro release studies of the chemically incorporated salicylic acid displayed widely tunable release profiles.

Indexed as

biodegradabledrug deliverymicrospheressalicylic acid

Identifiers

PMID23420391
PMCPMC3571728

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.